Long Term Nebulised Gentamicin in Patients With Bronchiectasis
Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Lothian
-
Edinburgh, Lothian, United Kingdom, EH16 4SA
- Royal Infirmary of Edinburgh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Bronchiectasis confirmed by HRCT of the chest
- Clinically stable (not requiring antibiotics for at least 4 weeks preceding the study start date)
- Aged 18-70
- Chronic sputum production > 5 mls for the majority of days in 3 months before enrolment
- Chronically colonized (on at least 2 occasions in the preceding 12 months) whilst clinically stable
- At least two exacerbations in the past year
- Patients able to tolerate a nebulized gentamicin challenge
- FEV1 > 30% predicted
- Smoking < 20 pack year history and ex-smokers >1 year.
Exclusion Criteria:
- Cystic fibrosis
- Emphysema on HRCT chest
- Thoracic surgery within the past 1 year
- Allergic bronchopulmonary aspergillosis
- Poorly controlled asthma ( > 20% diurnal variation in peak expiratory flows despite treatment)
- Unstable angina or uncontrolled congestive cardiac failure
- Active malignancy
- Pregnancy or breast feeding
- Creatinine clearance < 30 mls/minute
- Vestibular instability
- Previous documented intolerance to aminoglycosides
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
Nebulised Gentamicin
|
Nebulised 80mg twice daily
|
|
Placebo Comparator: 2
Nebulised 0.9% Saline
|
Nebulised 4mls 0.9% Saline twice daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reduction in bacterial load
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
airways and systemic inflammation
Time Frame: 1 year
|
1 year
|
|
Spirometry and exercise capacity
Time Frame: 1 year
|
1 year
|
|
Exacerbation frequency
Time Frame: 1 year
|
1 year
|
|
Health Related Quality of Life
Time Frame: 1 Year
|
1 Year
|
|
Long term safety with nebulised Gentamicin
Time Frame: 1 Year
|
1 Year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Adam T Hill, MBChB MD, NHS Lothian and University of Edinburgh
Publications and helpful links
General Publications
- Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012 Oct 1;186(7):657-65. doi: 10.1164/rccm.201203-0487OC. Epub 2012 Jun 28.
- Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011 Feb 15;183(4):491-9. doi: 10.1164/rccm.201005-0756OC. Epub 2010 Sep 24.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CZB/4/451
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.